Pfizer Inc. today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
Acceleware® Ltd. (TSXV: AXE) (“Acceleware” or the “Company”), today announced its financial and operating results for the three months ended March ...
The latest Census Bureau data shows that the post-COVID population rebound for many metropolises stalled or reversed in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results